The dual SGLT1/2* inhibitor considerably reduced the risk of the composite outcome of cardiovascular deaths, hospital admission for heart failure, and emergency visits for heart failure in individuals with type 2 diabetes and chronic kidney disease, irrespective of albuminuria status, as per the SCORED trial presented at ADA 2021. 

METHODS: In the multicentre, double-blind trial, 10 584 patients with T2D and CKD were randomized 1”1 to receive sotagliflozin or a placebo. 

RESULTS: The revised primary composite endpoint of total CV deaths, HHF, and urgent HF visits were significantly reduced by 26 percent with sotagliflozin vs. placebo (events per 100 patient-years, 5.6 vs. 7.5; hazard ratio [HR], 0.74; p=0.0004). The benefits were seen early in the treatment; the curves separated almost immediately. The benefit of sotagliflozin became considerably significant by 95 days when the HR was 0.70, with a p-value of 0.038. The total CV deaths, Mis, and strokes were reduced by 32 percent and 34 percent in risk, respectively. 

CONCLUSIONS: With a careful patient selection, sotagliflozin was generally well tolerated. The results of the trial further provided evidence to the fact that the overall benefit of this new class of glucose-lowering agents. Most individuals with T2D and either kidney disease or heart failure should be examined to initiate an SGLT inhibitor. 

Reference: Toh P. Sotagliflozin SCOREs in T2D patients with kidney disease. July 31, 2021. Accessed on September 17, 2021, from https://specialty.mims.com/topic/sotagliflozin-scores-in-t2d-patients-with-kidney-disease-?channel=endocrinology&elq_mid=56335&elq_cid=43297